ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 224.4 DKK 0.18% Market Closed
Market Cap: 45.5B DKK

ALK-Abello A/S
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ALK-Abello A/S
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
ALK-Abello A/S
CSE:ALK B
Net Issuance of Common Stock
-kr6m
CAGR 3-Years
N/A
CAGR 5-Years
18%
CAGR 10-Years
N/A
Novo Nordisk A/S
CSE:NOVO B
Net Issuance of Common Stock
-kr8.9B
CAGR 3-Years
28%
CAGR 5-Years
11%
CAGR 10-Years
6%
H Lundbeck A/S
CSE:HLUN A
Net Issuance of Common Stock
-kr46m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Net Issuance of Common Stock
kr5.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ALK-Abello A/S
Glance View

Market Cap
49.7B DKK
Industry
Pharmaceuticals

ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets. The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.

ALK B Intrinsic Value
197.93 DKK
Overvaluation 12%
Intrinsic Value
Price

See Also

What is ALK-Abello A/S's Net Issuance of Common Stock?
Net Issuance of Common Stock
-6m DKK

Based on the financial report for Sep 30, 2025, ALK-Abello A/S's Net Issuance of Common Stock amounts to -6m DKK.

What is ALK-Abello A/S's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
18%

Over the last year, the Net Issuance of Common Stock growth was 82%.

Back to Top